(Modotuximab)Biosimilar Reference Antibody-GS40444 新品

货号：GS40444

Modotuximab is a chimeric (mouse/human) IgG1‑kappa monoclonal antibody that specifically targets the human epidermal growth factor receptor (EGFR). As an IgG1 isotype, it is designed to engage immune effector functions such as antibody‑dependent cellular cytotoxicity (ADCC) and complement‑dependent cytotoxicity (CDC). By binding to EGFR, it blocks the interaction between the receptor and its natural ligands (e.g., EGF, TGF‑α), inhibiting downstream signaling pathways (e.g., MAPK, PI3K/AKT) that drive tumor cell proliferation, survival, and metastasis. It is being developed as a potential therapeutic agent for EGFR‑expressing solid tumors, such as colorectal cancer, non‑small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma.